Abstract
Cardiogenic shock (CS) is a hemodynamic syndrome that can progress to systemic metabolic derangements and end-organ dysfunction. Prior studies have reported hemodynamic parameters at the time of admission to be associated with mortality but hemodynamic trajectories in CS have not been well described. We studied the association between hemodynamic profiles and their trajectories and in-hospital mortality in patients with CS due to heart failure (HF-CS) and acute myocardial infarction (MI-CS). Using data from the large multicenter Cardiogenic Shock Working Group (CSWG) registry, we analyzed hemodynamic data obtained at the time of pulmonary artery catheter (PAC) insertion (dataset at baseline) and at PAC removal or death (dataset at final time point). Univariable regression analyses for prediction of in-hospital mortality were conducted for baseline and final hemodynamic values, as well as the interval change (delta-P). Data was further analyzed based on CS etiology and survival status. A total of 2260 patients with PAC data were included (70% male, age 61 ± 14 years, 61% HF-CS, 27% MI-CS). In-hospital mortality was higher in the MI-CS group (40.1%) compared with HF-CS (22.4%, P <.01). In the HF-CS cohort, survivors exhibited lower right atrial pressure (RAP), pulmonary artery pressure (PAP), cardiac output/index (CO/CI), lactate, and higher blood pressure (BP) than nonsurvivors at baseline. In this cohort, during hospitalization, improvement in metabolic (aspartate transaminase, lactate), BP, hemodynamic (RAP, pulmonary artery pulsatility index [PAPi], pulmonary artery compliance for right-sided profile and CO/CI for left-sided profile), had association with survival. In the MI-CS cohort, a lower systolic BP and higher PAP at baseline were associated with odds of death. Improvement in metabolic (lactate), BP, hemodynamic (RAP, PAPi for right-sided profile and CO/CI for left-sided profile) were associated with survival. In a large contemporary CS registry, hemodynamic trajectories had a strong association with short-term outcomes in both cohorts. These findings suggest the clinical importance of timing and monitoring hemodynamic trajectories to tailor management in patients with CS.
Original language | English (US) |
---|---|
Pages (from-to) | 1196-1207 |
Number of pages | 12 |
Journal | Journal of Cardiac Failure |
Volume | 30 |
Issue number | 10 |
DOIs | |
State | Published - Oct 2024 |
Funding
Dr. Kapur has received consulting honoraria and institutional grant support from Abbott Laboratories, Abiomed Inc, Boston Scientific, Medtronic, LivaNova, Getinge, and Zoll. Dr. Kanwar has served on the advisory board for Abiomed Inc. Dr. Garan has served as a consultant for NuPulseCV; has served on the scientific advisory board for Abiomed; and is a recipient of research support from Verantos and Abbott. Dr. Hernandez-Montfort has served as a consultant for Abiomed Inc. Dr. Abraham has served as a consultant for Abbott Laboratories and Abiomed Inc. Dr. Nathan has received consulting honoraria from Abiomed, Getinge, and CSI. Dr. Hall has served as a consultant to Abiomed, Abbott, and Medtronic. Dr. Mahr has served as a consultant to Abbott, Abiomed, and Syncardia. Dr. Burkhoff has received an unrestricted, educational grant from Abiomed Inc. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Keywords
- Cardiogenic shock
- heart failure
- hemodynamics
- Interventional Cardiology
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine